Vandetanib with docetaxel improve lung cancer survival

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

The findings, presented today at the American Society of Clinical Oncology's annual meeting, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer. Roy Herbst, M.D., Ph.D., professor and chief of the section of M. D. Anderson's Department of Thoracic/Head and Neck Medical Oncology, presented the findings on ASCO's press program.

"This study shows that an oral tyrosine kinase inhibitor can be combined with chemotherapy safely and effectively to provide systematic benefit to patients with this life-threatening disease," said Herbst. "This study will have immediate clinical implications. Still, we need to build on this research and turn our focus toward better identifying molecular markers involved, with the ultimate goal of personalizing our patient's care."

The therapy is unique in that it's a dual inhibitor and targets the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). It is the first single agent in lung cancer to target both receptors, said Herbst, the study's international principal investigator.

"Both receptors are active in lung cancer. EGFR targets the tumor cell and VEGF targets the blood vessels, so, with vandetanib, we're really targeting the entire tumor environment at the same time," explained Herbst. "As a dual inhibitor, it also may provide cost-savings to patients in that they can now potentially take one therapy instead of two."

According to the American Cancer Society, lung cancer accounts for the most cancer-related deaths. In 2009, 219,440 are expected to be diagnosed and 159,390 will likely die from the disease.

The ZODIAC, (Zactima in cOmbination with Docetaxel In non-smAll cell lung Cancer) study enrolled 1,391 patients with non-small cell lung cancer from 198 centers between May 2006 and April 2008; all had received chemotherapy previously. Participants were randomized to receive either docetaxel and placebo, or docetaxel and vandetanib. The median follow-up was 12.8 months and the study's primary endpoint was progression-free survival.

Patients in the combination arm had a 21 percent reduction in disease progression, compared to those who received docetaxel alone (hazard ratio, .79), and their median progression-free survival was 17.3 weeks. In contrast, the median progression-free survival in the control arm was 14 weeks. While it trended positive, however, there was no statistical difference in overall survival in the two groups. There was a statistically significant improvement in the time to worsening of symptoms (hazard ratio, .77).

"Obviously, our ultimate goal is to always improve survival for our patients, however the improved time to progression with less of a number of significant effects is important," said Herbst. "This is certainly a drug, where, if we could identify molecular parameters that predict response, we could some day take a group that's receiving docetaxel and vandetanib and see them do even better. We're not there yet, but hopefully this study will serve as the foundation for the merger of personalization and discovery with the now-proven safety and efficacy."

In terms of side effects, patients who received vandetanib experienced more diarrhea, rash and neutropenia. However, they experienced less of the significant side effects - nausea, vomiting, and anemia - than those who received docetaxel alone. The lack of significant side effects is quite striking, said Herbst, because other agents that target VEGF are associated with increased toxicity, including pulmonary bleeding.

As follow up, Herbst plans to update the survival data later this year. Other studies with vandetanib in lung cancer as a single agent, as well as in thyroid cancer, are currently ongoing.

In addition to Herbst, other authors on the study include: Yan Sun, Cancer Hospital, Bejing, China; Sönke Korfee, West German Tumor Center, University Duisburg-Essen; Paul Germonpré, Antwerp University Hospital, Belgium; Nagahio Saijo, National Cancer Center Hospital East, Chiba, Japan; Caichun Zhou, Tongji University, Shanghai, China; Jie Wang, Beijing Institute for Cancer Research, Beijing, China; Bruce Johnson, Dana-Farber Cancer Institute; and Peter Langmuir, Hiroomi Tada, Sarah Kennedy, all with AstraZeneca.

Herbst has been a consultant for and has received research support from AstraZeneca.


(Editor compiled and published Vandetanib with docetaxel improve lung cancer survival at HealthNewsTrack on June 1, 2009 sourced from University of Texas M. D. Anderson Cancer Center - http://www.mdanderson.org/)

Lung Cancer - recent articles and current news stories:

- New lung cancer test could accurately guide treatment for people with lung cancer
- 20% reduction in lung cancer mortality with low dose CT vs chest X ray
- Gene expression changes in nasal cells may help identify lung cancer
- Genetic test for lung cancer risk prompts smokers to quit
- Vitamin B6 lowers risk of lung cancer

Lung Cancer article/news source:

Read more health articles from University of Texas M. D. Anderson Cancer Center and health articles from USA.

Lung Cancer - search related terms:

Adenocarcinoma, Cancer, Chemotherapy, Docetaxel, Lung cancer, Oncology, Tumor, Vandetanib,
Lung Cancer books,

Subscribe to Health News by Email

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.28